Insider Selling: Liquidia (NASDAQ:LQDA) CFO Sells 18,938 Shares of Company Stock

Liquidia Corporation (NASDAQ:LQDA) CFO Michael Kaseta sold 18,938 shares of the stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $28.48, for a total transaction of $539,354.24. Following the completion of the sale, the chief financial officer owned 340,148 shares in the company, valued at $9,687,415.04. This represents a 5.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Trading Down 3.1%

Liquidia stock traded down $0.86 during midday trading on Tuesday, hitting $26.81. 3,092,611 shares of the stock were exchanged, compared to its average volume of 5,078,983. The company has a fifty day simple moving average of $63.40 and a two-hundred day simple moving average of $61.76. Liquidia Corporation has a 52 week low of $21.94 and a 52 week high of $93.61. The stock has a market capitalization of $2.40 billion, a PE ratio of 19.57 and a beta of 0.61. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The firm had revenue of $171.68 million for the quarter, compared to analyst estimates of $168.48 million. During the same quarter in the prior year, the firm posted ($0.49) EPS. The firm’s revenue for the quarter was up 1842.1% compared to the same quarter last year. Equities research analysts anticipate that Liquidia Corporation will post 2.05 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on LQDA. Needham & Company LLC reduced their price target on shares of Liquidia from $110.00 to $72.00 and set a “buy” rating on the stock in a research report on Thursday, October 1st. Wedbush set a $58.00 price objective on shares of Liquidia in a research report on Friday, October 2nd. Piper Sandler set a $129.00 price objective on shares of Liquidia in a research report on Friday, July 24th. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $30.00 price objective (down from $108.00) on shares of Liquidia in a research note on Friday, October 2nd. Finally, Bank of America raised their price objective on Liquidia from $79.00 to $92.00 and gave the stock a “neutral” rating in a research note on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Liquidia currently has a consensus rating of “Hold” and a consensus target price of $83.69.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. WINTON GROUP Ltd acquired a new stake in Liquidia in the 2nd quarter valued at approximately $335,000. Arizona State Retirement System lifted its stake in Liquidia by 5.4% in the 2nd quarter. Arizona State Retirement System now owns 17,627 shares of the company’s stock valued at $1,405,000 after acquiring an additional 900 shares in the last quarter. Nykredit A S bought a new stake in Liquidia in the 2nd quarter valued at approximately $177,000. Corient Private Wealth LP acquired a new position in Liquidia during the 2nd quarter worth approximately $758,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Liquidia during the 2nd quarter worth approximately $1,236,000. 64.54% of the stock is currently owned by institutional investors.

Key Headlines Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reached a global settlement with United Therapeutics that resolves all six pending lawsuits and allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH). Eliminating years of patent, antitrust and trade-secret litigation reduces regulatory and commercial uncertainty. Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were $222.7 million, while cash and cash equivalents stood at $396.1 million at September 30. Management said it expects to fund the settlement and planned clinical programs from cash and ongoing sales without additional financing. The company also plans to continue developing YUTREPIA and L606.
• Neutral Sentiment: Multiple executives and insiders—including the CEO, CFO, CAO and general counsel—sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales reduced individual holdings but were not discretionary open-market transactions, making them a limited standalone signal of management confidence. Liquidia insider sale filing
• Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million: $175 million within 30 business days, $145.4 million in installments during 2027 and $60.3 million related to the antitrust litigation. The outflows could materially reduce its cash cushion and constrain investment, even though management expects to rebuild cash through YUTREPIA sales.
• Negative Sentiment: The company agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label, limiting the product’s addressable market. Liquidia also ended promotion of Treprostinil Injection, eliminating associated commercial revenue opportunities.
• Negative Sentiment: Recent insider activity remains heavily tilted toward selling—106 sales versus one purchase over six months—and a report highlighted a chairman’s share sale. Separately, a law firm announced an investor investigation related to disclosure of YUTREPIA litigation risks, adding potential reputational and legal uncertainty. Liquidia Negatively Rated Stock Pick of the Week

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).